EMD Millipore, the Life Science division of Merck KGaA, has entered an exclusive agreement to sell recombinant human insulin manufactured by Julphar Diabetes, a pharmaceutical production company based in the United Arab Emirates. The insulin is of non-animal origin and will be marketed under EMD Millipore's CellPrime brand. CellPrime Insulin stimulates the proliferation of cells and aids in carbohydrate metabolism, helping to ensure the long-term viability of various cell lines, according to an EMD Millipore statement.
"CellPrime Insulin will help the biopharmaceutical industry enhance cell culture performance without sacrificing safety," said Burghard Freiberg, senior vice president Pharm Chemicals Solutions. "Owing to its non-animal origin, its consistent manufacturing process and the traceability of its raw materials it enables manufacturers of monoclonal antibodies and recombinant biologics to use an insulin supplement that is both safe and effective."
Joe Saldanha, general manger of Julphar Diabetes, said, “This agreement marks a significant achievement for Julphar Diabetes and demonstrates the global impact that the state of the art manufacturing facility is set to make on the diabetes drug industry worldwide. We are proud to be associated with such a strong partner in the life science sector.”